Literature DB >> 19302430

When the clinical trials raise more questions than answers: blood pressure controversy beyond the TRANSCEND results.

Vivencio Barrios1, Carlos Escobar, Rocio Echarri, Alberto Calderon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19302430      PMCID： PMC8673203          DOI： 10.1111/j.1751-7176.2009.00074.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  4 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Evolution of blood pressure control in Spain.

Authors:  Vivencio Barrios; José R Banegas; Luis M Ruilope; José L Rodicio
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

3.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

4.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.